Company Comparison
Forty Seven vs 23andMe
Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.
| Metric | Forty Seven | 23andMe |
|---|---|---|
| Sector | Biotech | Biotech |
| Headquarters | Menlo Park, California | South San Francisco, California |
| Founded | 2014 | 2006 |
| Status | Active | Active |
| Last Funding Stage | Series C | — |
| Total Funding | $320M | — |
| Valuation | — | — |
What They Build
Forty Seven
Biotechnology company developing cancer immunotherapies targeting the CD47 pathway to enhance immune system recognition of cancer cells.
23andMe
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California.
Key Investors
Forty Seven
Sector Overlap
Both Forty Seven and 23andMe operate in Biotech.
Browse all Biotech companies →